Literature DB >> 21093416

Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.

Lucio G Costa1, Gennaro Giordano, Clement E Furlong.   

Abstract

Paraoxonase 1 (PON1) is a high density lipoprotein (HDL)-associated enzyme displaying esterase and lactonase activity. PON1 hydrolyzes several organophosphorus (OP) insecticides and nerve agents, a number of exogenous and endogenous lactones, and metabolizes toxic oxidized lipids of low density lipoproteins (LDL) and HDL. As such, PON1 plays a relevant role in determining susceptibility to OP toxicity, cardiovascular diseases and several other diseases. Serum PON1 activity in a given population can vary by at least 40-fold. Most of this variation can be accounted for by genetic polymorphisms in the coding region (Q192R, L55M) and in the promoter region (T-108C). However, exogenous factors may also modulate PON1 activity and/or level of expression. This paper examines various factors that have been found to positively modulate PON1. Certain drugs (e.g. hypolipemic and anti-diabetic compounds), dietary factors (antioxidants, polyphenols), and life-style factors (moderate alcohol consumption) appear to increase PON1 activity. Given the relevance of PON1 in protecting from certain environmental exposure and from cardiovascular and other diseases, there is a need for further mechanistic, animal, and clinical research in this area, and for consideration of possible alternative strategies for increasing the levels and activity of PON1.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21093416      PMCID: PMC3077125          DOI: 10.1016/j.bcp.2010.11.008

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  97 in total

1.  Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1.

Authors:  M C Blatter-Garin; B Kalix; S De Pree; R W James
Journal:  Diabetologia       Date:  2003-03-22       Impact factor: 10.122

2.  The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes.

Authors:  A J Wallace; W H Sutherland; J I Mann; S M Williams
Journal:  Eur J Clin Nutr       Date:  2001-11       Impact factor: 4.016

3.  Hepatic effects of rosiglitazone in rats with the metabolic syndrome.

Authors:  Zvi Ackerman; Mor Oron-Herman; Orit Pappo; Edna Peleg; Rifaat Safadi; Hemda Schmilovitz-Weiss; Maria Grozovski
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-03-04       Impact factor: 4.080

4.  The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase.

Authors:  Andrea Kassai; László Illyés; Hossein Z Mirdamadi; Ildiko Seres; Tímea Kalmár; Mária Audikovszky; György Paragh
Journal:  Clin Biochem       Date:  2006-06-09       Impact factor: 3.281

5.  Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

Authors:  S Billecke; D Draganov; R Counsell; P Stetson; C Watson; C Hsu; B N La Du
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

6.  Enhanced PON1 activity in the kidneys of cyclophosphamide treated rats may play a protective role as an antioxidant against cyclophosphamide induced oxidative stress.

Authors:  Premila Abraham; Emila Sugumar
Journal:  Arch Toxicol       Date:  2007-09-14       Impact factor: 5.153

7.  Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation.

Authors:  Maokai Gong; Mamatha Garige; Ravi Varatharajalu; Philippe Marmillot; Chandra Gottipatti; Leslie Castillo Leckey; Raj M Lakshman
Journal:  Biochem Biophys Res Commun       Date:  2009-01-12       Impact factor: 3.575

Review 8.  Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity.

Authors:  Jordi Camps; Judit Marsillach; Jorge Joven
Journal:  Mini Rev Med Chem       Date:  2009-07       Impact factor: 3.862

9.  Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization.

Authors:  Su Duy Nguyen; Dai-Eun Sok
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

10.  Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning.

Authors:  Richard C Stevens; Stephanie M Suzuki; Toby B Cole; Sarah S Park; Rebecca J Richter; Clement E Furlong
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-18       Impact factor: 11.205

View more
  54 in total

1.  Paraoxonase 1 activity in chylomicrons and VLDL: the effect of type 2 diabetes and meals rich in saturated fat and oleic acid.

Authors:  Patrick J Manning; Sylvia A de Jong; Anne R Ryalls; Wayne H F Sutherland
Journal:  Lipids       Date:  2011-12-10       Impact factor: 1.880

Review 2.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 3.  Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection.

Authors:  Lucio G Costa; Rian de Laat; Khoi Dao; Claudia Pellacani; Toby B Cole; Clement E Furlong
Journal:  Neurotoxicology       Date:  2013-09-04       Impact factor: 4.294

4.  Lack of ligand-selective binding of the aryl hydrocarbon receptor to putative DNA binding sites regulating expression of Bax and paraoxonase 1 genes.

Authors:  Danica E DeGroot; Ai Hayashi; Michael S Denison
Journal:  Arch Biochem Biophys       Date:  2013-11-04       Impact factor: 4.013

Review 5.  Paraoxonases: metabolic role and pharmacological projection.

Authors:  Carlos Moya; Salvador Máñez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-02-06       Impact factor: 3.000

6.  Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer.

Authors:  H Balci; H Genc; C Papila; G Can; B Papila; H Yanardag; H Uzun
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

Review 7.  Pharmacologic strategies to target oxidative stress in heart failure.

Authors:  Zain Ahmed; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2012-03

8.  Paraoxonases-1, -2 and -3: What are their functions?

Authors:  Clement E Furlong; Judit Marsillach; Gail P Jarvik; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-05-26       Impact factor: 5.192

Review 9.  Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.

Authors:  Lucio G Costa; Gennaro Giordano; Toby B Cole; Judit Marsillach; Clement E Furlong
Journal:  Toxicology       Date:  2012-07-31       Impact factor: 4.221

Review 10.  Dietary fats and health: dietary recommendations in the context of scientific evidence.

Authors:  Glen D Lawrence
Journal:  Adv Nutr       Date:  2013-05-01       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.